Researchers at Durham University, working with Pleco Therapeutics in the Netherlands, have identified an unexpected mechanism that may help explain why some lung cancers become resistant to chemotherapy. The culprit is not necessarily a single toxic metal, but the combined activity of several metals accumulating inside tumour cells. In laboratory experiments and mouse models, low concentrations of copper, manganese, zinc, chromium, cadmium and lead worked together to reduce the effectiveness of several commonly used chemotherapy drugs, even though the individual metals produced little or no resistance on their own. The discovery suggests that the chemical environment inside a tumour may be just as important as the genetic mutations traditionally associated with treatment failure.
Metals have long been connected with cancer biology. Copper, zinc and iron, for example, are essential nutrients involved in metabolism, DNA synthesis and the control of oxidative stress. Other metals, including cadmium, chromium and lead, are toxic and can enter the body through smoking, industrial pollution, contaminated dust, food or water. Previous research has often examined these elements separately, asking how one metal affects cancer cells. The Durham-led study takes a different approach by examining what happens when several metals are present at the same time. Its central finding is that combinations of metals can cooperate, creating a biological effect that is far greater than would be expected from exposure to any one metal alone.
The researchers exposed lung cancer cells to low, non-toxic levels of the metals associated with smoking and environmental contamination. At these concentrations, the cells remained alive and did not show the kind of widespread damage expected from acute metal poisoning. Yet after the metals accumulated inside the cells, the cancer became markedly less responsive to multiple chemotherapy agents. This distinction is important because it mirrors a possible real-world situation in which tumour cells are not overwhelmed by a single large dose of a toxic element, but are instead exposed to a mixture of metals over time. The findings indicate that a tumour could develop a protective state without appearing obviously damaged or poisoned.
The resistance was also reversible, a feature that makes the discovery especially significant for future treatment strategies. When the metal burden inside the cancer cells was reduced, the cells became sensitive to chemotherapy again. This suggests that metal-driven resistance may not be a permanent consequence of new genetic mutations. Instead, it may function partly as a flexible, chemically induced survival programme. Cancer cells can alter their internal metabolism and stress responses in response to their surroundings, and the study indicates that a metal-rich environment may push them into a state that allows them to withstand drugs that would normally kill them.
The team identified a possible way to interrupt this process using MiADMSA, a small molecule originally developed as a treatment for metal poisoning. MiADMSA is a membrane-permeable chelator, meaning it can cross the cell membrane and bind metal ions inside the cell. Chelators are compounds that capture metals through chemical interactions, reducing their availability to participate in biological reactions. In the Durham experiments, MiADMSA was able to remove multiple metals rather than targeting only one element. When it was combined with chemotherapy, the chelator restored drug sensitivity in lung cancer cells grown in the laboratory and substantially reduced tumour growth in mouse models exposed to the metal mixtures.
The biological explanation appears to involve oxidative stress. Chemotherapy drugs often damage cancer cells by disrupting DNA, interfering with cell division or increasing the production of reactive oxygen species, chemically reactive molecules that can damage proteins, membranes and genetic material. Tumour cells commonly adapt to this pressure by activating antioxidant systems and other stress-response pathways. The researchers believe that the combined metals intensify or reshape these responses, allowing the cancer cells to tolerate the oxidative damage generated by chemotherapy. Rather than simply acting as poisons, the metals may therefore help cancer cells prepare for the very type of molecular assault that treatment is designed to deliver.
This mechanism could help explain why chemotherapy resistance sometimes emerges in tumours whose known genetic features do not fully account for treatment failure. Cancer is not only a disease of altered DNA; it is also influenced by nutrients, oxygen levels, inflammation, metabolism and the surrounding tissue environment. Metals can affect enzymes, cellular signalling, mitochondrial function and the regulation of genes involved in survival. When several metals are present together, their effects may overlap or reinforce one another, producing a form of chemical cooperation. That possibility raises the prospect that some treatment-resistant tumours could be profiled not only for mutations, but also for their metal content and the stress pathways activated by it.
The potential clinical implications are considerable, although the work remains at the preclinical stage. A chemotherapy-and-chelator combination could, in principle, make existing drugs more effective without requiring higher doses. If treatment sensitivity can be restored, patients might eventually receive lower amounts of chemotherapy while achieving a comparable or improved anti-tumour effect, potentially reducing side effects. However, translating the findings into human treatment will require careful testing. Metals such as copper, zinc and iron are essential for healthy cells, and removing them indiscriminately could cause harm. Researchers will need to determine the appropriate dose, timing and selectivity of MiADMSA, as well as establish whether it can remove harmful metal combinations from tumours without disrupting normal tissues.
The study may also have relevance beyond lung cancer. Abnormal metal accumulation has been reported in several tumour types, and many cancers exist in environments shaped by smoking, pollution, occupational exposure, inflammation or altered metabolism. The next stage of research will need to establish whether multi-metal cooperation contributes to resistance in breast, colorectal, liver or other cancers, and whether tumour metal profiles can predict which patients are most likely to benefit from chelation therapy. For now, the findings offer a striking new perspective on chemotherapy failure: a tumour’s resistance may be influenced not only by its mutations, but also by the invisible mixture of metals stored within its cells. The fact that this resistance was reversed in experimental models makes metal biology a potentially important new frontier in cancer treatment research.
Subject of Research: Multi-metal cooperation in lung cancer chemotherapy resistance and its reversal using the membrane-permeable chelator MiADMSA.
Article Title: “Multi-metal cooperation drives chemoresistance in lung cancer and is reversed by the membrane-permeable chelator MiADMSA”
Web References: https://doi.org/10.1038/s41420-026-03222-8
References: P. Muller et al., “Multi-metal cooperation drives chemoresistance in lung cancer and is reversed by the membrane-permeable chelator MiADMSA,” Cell Death Discovery, 2026.
Keywords: lung cancer, chemotherapy resistance, metal toxicity, copper, manganese, zinc, chromium, cadmium, lead, MiADMSA, chelation therapy, reactive oxygen species, cancer treatment, tumour microenvironment
Tags: cadmiumchemical environment influence on chemotherapy efficacychromiumcombined metal effects on chemotherapy resistanceenvironmental metals and lung cancerheavy metals and tumor microenvironmentlead in lung cancerlung cancer chemotherapy resistancemanganesemetal accumulation in cancer cellsmetal-induced oxidative stress in cancer cellsmulti-metal toxicity in cancer treatmentrole of coppertumor metal chelation therapyzinc
